MetaCap

Compass Therapeutics (CMPX) vs enGene Therapeutics (ENGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

enGene Therapeutics (ENGN) has outperformed Compass Therapeutics (CMPX) over the past year, losing 75.0% versus a loss of 85.9%. Compass Therapeutics is the larger company by market cap ($123.9 million vs $116.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CMPX-85.87%ENGN-75.00%
+83%-6%-96%
Nov 21, 20251 yearNov 20, 2026
CMPX-61.98%ENGN-82.35%
+277%+88%-102%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CMPX versus ENGN key metrics
MetricCMPXENGN
Share price$0.6882$1.74
Market cap$123.94M$116.61M
1-day change+1.43%-1.14%
YTD return-87.18%-80.73%
1-year return-85.87%-75.00%
5-year return-78.63%—
EPS (TTM)$-0.46$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-66.49M$-117.30M
52-week high$6.88$12.25
52-week low$0.57$1.40
Distance from 52-week high-90.00%-85.80%
Analyst consensusbuybuy
Avg. price target upside+664.31%+146.55%
Average volume3.88M1.12M
Shares outstanding180.09M67.02M
Employees3981
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ENGN has outperformed CMPX by 10.9 percentage points over the past year.

About Compass Therapeutics

CMPX stock →

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

CMPX vs ENGN FAQ

Which is bigger, Compass Therapeutics or enGene Therapeutics?

Compass Therapeutics (CMPX) is larger, with a market capitalization of $123.94M compared with $116.61M for enGene Therapeutics (ENGN).

Which stock has performed better over the past year, CMPX or ENGN?

ENGN returned -75.00% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.

Are Compass Therapeutics and enGene Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons